News | News By Subject | News by Disease News By Date | Search News

Huntington's disease News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
FDA Wants Teva (TEVA) to Re-Analyze the Blood Levels of Certain Metabolites of Huntington Disease Drug     5/31/2016
Three Big Obstacles Bay Area's Raptor (RPTP) Needs to Overcome     3/22/2016
Teva (TEVA) Snags Breakthrough Therapy Designation from the FDA for Huntington's Disease Drug     11/9/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
SoCal's Auspex Pharmaceuticals (ASPX) Soars 90% On Huntington's Disease Drug Trial Data     12/18/2014
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Omeros Corporation (OMER) Suspends Enrollment In Huntington's Disease Trial; Stock Down 11.36% At 8:40AM ET On Tuesday     10/21/2014
Raptor Pharmaceutical Inc. (RPTP) Surges As Huntington's Drug Meets Study Endpoints     2/21/2014
PRANA Biotechnology (PRAN) Soars As Brain Disorder Drug Succeeds In Phase 2 Trial; Stock Up +39.31% At Market Close (February 18, 2014)     2/19/2014
Roche (RHHBY) and Isis Pharmaceuticals, Inc. (ISIS) Form $392 Million Alliance for Huntington's Disease     4/8/2013
Medivation, Inc. (MDVN), Pfizer Inc. (PFE) Huntington's Drug Fails To Meet Test Goals     4/12/2011
Neurosearch A/S (NEUR.CO) Shares Plunge as FDA Wants More Data     3/24/2011
Neurosearch A/S (NEUR.CO) Announces Positive Top-line Results from Phase III Huntexil(R) Study in Huntington's Disease     2/3/2010
Pfizer Inc. (PFE) (JOBS) and Medivation, Inc. (MDVN) Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease     7/30/2009

News from Around the Web
Aspirin Targets Key Protein In Alzheimer's, Parkinson's, Hungtinton's, Johns Hopkins University Study     12/1/2015
Synthetic Oil Drug May Bring Promise For Huntington's Disease, Pitié-Salpêtrière University Hospital Study     1/8/2015
Popular Weight-Lifting Supplement May Slow Huntington Disease, Massachusetts General Hospital Study     2/11/2014
University of Mainz Researchers Find Controlling Element of Huntington's Disease     2/27/2013
Pathology of Huntington's Disease Identified, Boston University School of Medicine Study     10/18/2012
Scientists Identify Protein Form Linked to Huntington's Disease, Gladstone Institute Study     11/1/2011
Compound May Provide Drug Therapy Approach for Huntington's Disease, UT Southwestern Medical Center Study     6/24/2011
Huntington's Disease Breakthrough: New Research Offers Promise of Medical Intervention, University of Leicester Study     6/10/2011
Leap Forward In Efforts To Develop Treatments For Huntington's Disease, Buck Institute for Age Research Study     7/29/2010
Scientists Make Important Step Toward Stopping Plaque-Like Formations in Huntington's Disease, Study in GENETICS     5/24/2010
Medivation, Inc. (MDVN) Alzheimer's Drug Dimebon Helps Huntington's, University of Rochester Study     2/9/2010
IKK May Act As Both Inhibitor And Promoter Of Huntington's Disease, Rockefeller University Study     12/21/2009
Gene Therapy Stalls Development Of Huntington's Disease In Mice, California Institute of Technology Study     11/9/2009
Nervous System Drug-by-design: Formulation May Slow Parkinson's, Alzheimer's, Huntington's, Tel Aviv University Study     10/27/2009
Scientists Uncover Culprit In Huntington's Disease, Johns Hopkins University Study     6/5/2009

Press Releases
Teva (TEVA) Announces FDA Acceptance Of Resubmitted New Drug Application For SD-809 For Treatment Of Chorea Associated With Huntington Disease     10/20/2016
Teva (TEVA) Announces Results from Exploratory 52-Week Phase 2 PRIDE-HD Study Of Pridopidine In Huntington Disease     9/19/2016
Vybion, Inc. Release: Novel Gene Therapy Drug For Huntington's Disease     8/24/2016
Vaccinex, Inc. Receives Orphan Drug Designation From U.S. FDA For Its Lead Antibody Product Candidate, VX15, As A Potential Treatment For Huntington’s Disease     8/24/2016
Vaccinex, Inc. Receives FDA Fast Track Designation For VX15 Antibody For The Treatment Of Huntington’s Disease     8/1/2016
Teva (TEVA) And The Huntington Study Group Announce Publication Of Pivotal Phase III Data On Deutetrabenazine (SD-809) In Huntington Disease From First-HD Trial In JAMA     7/5/2016
WAVE Life Sciences (WVE) Receives Orphan Drug Designation From FDA For Its Lead Candidate Designed To Treat Huntington’s Disease     6/21/2016
uniQure (QURE) Announces Preclinical Proof Of Concept For Gene Therapy Approach In Huntington's Disease     3/23/2016
Raptor (RPTP) Plans To Advance RP103 In A Registration Study In Huntington's Disease Based On Favorable Treatment Effects At 36 Months In CYST-HD Trial     12/10/2015
Dr. Juan Sanchez To Lead Verde's Huntington Disease Study     10/19/2015
Verde Science Announces Plan To Study Cannabis Preparation For Treatment Of Huntingdon's Disease     10/12/2015
Sangamo BioSciences (SGMO) And Shire (SHPG) Restructure Collaboration To Accelerate Development Of ZFP Therapeutics For The Treatment Of Hemophilia And Huntington's Disease     9/2/2015
PRANA Biotechnology (PRAN) Reports FY15 Financial Results     8/27/2015
Teva (TEVA) Announces FDA Acceptance Of NDA For SD-809 For Treatment In Huntington Disease     8/12/2015
Vaccinex, Inc. Announces The Initiation Of A Phase 2 Clinical Trial Of Its Investigational VX15/2503 Antibody In Huntington's Disease (The SIGNAL Trial)     6/24/2015

//-->